 When bound to CTLA-4, CD86 can be removed from the surface of an APC and onto the T-reg cell in a process called trogocytosis.Blocking this process with anit-CTLA-4 antibodies is useful for a specific type of cancer immunotherapy called cancer therapy by inhibition of negative immune regulation.Japanese immunologist Tasuku Honjo and American immunologist James P. Allison won the Nobel Prize in Physiology or Medicine in 2018 for their work on this topic.